According to a report from National Nurses United, 81.6 percent of nurses said they experienced workplace violence in 2023.

Ask any healthcare worker, and they will have their own story of workplace violence. In the early years of my career, I narrowly missed encountering a gunman in the hospital ER solely because I forgot something and had to return upstairs. While tragedy was avoided in my case, too often, it is not. Such incidents are not isolated; in fact, they are becoming disturbingly common.

According to a report from National Nurses United, 81.6 percent of nurses said they experienced workplace violence in 2023.

As a physician, providing excellent patient care has always been my priority; however, any type of workplace violence disrupts quality care. When the supposedly safe spaces of healing and learning become targets, we must look at ways beyond hardening the exteriors to help prevent such violence within buildings.

For our healthcare systems, the answer may lie within our schools.

Since we lost our daughter and 16 of her classmates and staff at Marjory Stoneman Douglas High School in Parkland, Florida, six years ago, my wife and I have been advocating for enhanced school safety measures for classrooms across the nation.

Seven states have passed Alyssa's Law, named for our daughter, which requires the installation of wearable panic alarm technology in education settings. These alarms, which instantly link every classroom to emergency personnel while also providing mass communication to all staff, serve as a lifeline in times of crisis. These wearable panic alarms are not just outfitted for classrooms: they can be utilized in any workplace setting, including a healthcare system.

Despite their difference in purpose, healthcare facilities and schools share the unique properties of community spaces. Healthcare facilities are safe havens for those who need healing and rest within our community. No one should fear for their safety going to the doctor. Just as lawmakers have rethought and revised school safety requirements, they should do the same for healthcare facilities. Wearable safety technology has emerged as a formidable solution to this pressing issue.

Wearable, mobile duress badge technology is tailor-made for the unique challenges faced by healthcare workers. It is discrete, easy to use, and can be customizable for each healthcare campus. Some duress badge providers have technology that equips nurses, doctors and staff with badges that display their location and the ability to signal the level of emergency with a push of a button. They can use one badge for all campuses within a healthcare system, and they do not have to wait to get in touch with a hospital operator to “sound the alarm” or risk escalating a situation by lunging for a wall-mounted panic button.

Mobile panic alarms offer a nuanced and efficient response mechanism. Whether a minor incident or a life-threatening crisis, healthcare professionals can instantly summon help, ensuring a swifter and more coordinated response.

Texas was one of the first states to take on this alarming trend of workplace violence by passing SB240 last session, mandating facilities to establish a workplace violence prevention plan. Similar legislation is playing out in other states, becoming a nationwide movement.

I know healthcare facilities' budgets are tight these days with unprecedented rising costs of care and lower reimbursement rates. Still, through my personal journey in advocating for safety improvements in our educational institutions, I have learned one thing: you must invest in the future.

The adoption of wearable panic alarms is not just a security upgrade; it's a commitment to the well-being of those who dedicate their lives to provide healing and care. It's about protecting our community spaces. Like any other, the healthcare environment should be a sanctuary, free from the fear of violence. As Alyssa’s Law gains traction nationally, the spotlight now turns to healthcare facilities to embrace this critical technology.

Time, as we know too well, equals life. Swift action can be the difference between tragedy and survival. Investing in wearable panic alarm technology is an investment in our healthcare workforce's safety, resilience, and mental well-being. As we advocate for students to have a safe place to thrive, I am doing the same for healthcare places. The time has come to make our healthcare facilities safe.

------

Dr. Ilan Alhadeff is the father of Alyssa Alhadeff, a victim of the February 14, 2018, school shooting at Marjory Stoneman Douglas High School, and co-founder of Make Our Schools Safe, a 501(c)(3) nonprofit organization dedicated to improving school safety.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston edtech company closes oversubscribed $3M seed round

fresh funding

Houston-based edtech company TrueLeap Inc. closed an oversubscribed seed round last month.

The $3.3 million round was led by Joe Swinbank Family Limited Partnership, a venture capital firm based in Houston. Gamper Ventures, another Houston firm, also participated with additional strategic partners.

TrueLeap reports that the funding will support the large-scale rollout of its "edge AI, integrated learning systems and last-mile broadband across underserved communities."

“The last mile is where most digital transformation efforts break down,” Sandip Bordoloi, CEO and president of TrueLeap, said in a news release. “TrueLeap was built to operate where bandwidth is limited, power is unreliable, and institutions need real systems—not pilots. This round allows us to scale infrastructure that actually works on the ground.”

True Leap works to address the digital divide in education through its AI-powered education, workforce systems and digital services that are designed for underserved and low-connectivity communities.

The company has created infrastructure in Africa, India and rural America. Just this week, it announced an agreement with the City of Kinshasa in the Democratic Republic of Congo to deploy a digital twin platform for its public education system that will allow provincial leaders to manage enrollment, staffing, infrastructure and performance with live data.

“What sets TrueLeap apart is their infrastructure mindset,” Joe Swinbank, General Partner at Joe Swinbank Family Limited Partnership, added in the news release. “They are building the physical and digital rails that allow entire ecosystems to function. The convergence of edge compute, connectivity, and services makes this a compelling global infrastructure opportunity.”

TrueLeap was founded by Bordoloi and Sunny Zhang and developed out of Born Global Ventures, a Houston venture studio focused on advancing immigrant-founded technology. It closed an oversubscribed pre-seed in 2024.

Texas space co. takes giant step toward lunar excavator deployment

Out of this world

Lunar exploration and development are currently hampered by the fact that the moon is largely devoid of necessary infrastructure, like spaceports. Such amenities need to be constructed remotely by autonomous vehicles, and making effective devices that can survive the harsh lunar surface long enough to complete construction projects is daunting.

Enter San Antonio-based Astroport Space Technologies. Founded in San Antonio in 2020, the company has become a major part of building plans beyond Earth, via its prototype excavator, and in early February, it completed an important field test of its new lunar excavator.

The new excavator is designed to function with California-based Astrolab's Flexible Logistics and Exploration (FLEX) rover, a highly modular vehicle that will perform a variety of functions on the surface of the moon.

In a recent demo, the Astroport prototype excavator successfully integrated with FLEX and proceeded to dig in a simulated lunar surface. The excavator collected an average of 207 lbs (94kg) of regolith (lunar surface dust) in just 3.5 minutes. It will need that speed to move the estimated 3,723 tons (3,378 tonnes) of regolith needed for a lunar spaceport.

After the successful test, both Astroport and Astrolab expressed confidence that the excavator was ready for deployment. "Leading with this successful excavator demo proves that our technology is no longer theoretical—it is operational," said Sam Ximenes, CEO of Astroport.

"This is the first of many implements in development that will turn Astrolab's FLEX rover into the 'Swiss Army Knife' of lunar construction. To meet the infrastructure needs of the emerging lunar economy, we must build the 'Port' before the 'Ship' arrives. By leveraging the FLEX platform, we are providing the Space Force, NASA, and commercial partners with a 'Shovel-Ready' construction capability to secure the lunar high ground."

"We are excited to provide the mobility backbone for Astroport's groundbreaking construction technology," said Jaret Matthews, CEO of Astrolab, in a release. "Astrolab is dedicated to establishing a viable lunar ecosystem. By combining our FLEX rover's versatility with Astroport's civil engineering expertise, we are delivering the essential capabilities required for a sustainable lunar economy."

---

This article originally appeared on CultureMap.com.

Houston biotech co. raises $11M to advance ALS drug development

drug money

Houston-based clinical-stage biotechnology company Coya Therapeutics (NASDAQ: COYA) has raised $11.1 million in a private investment round.

India-based pharmaceuticals company Dr. Reddy’s Laboratories Inc. led the round with a $10 million investment, according to a news release. New York-based investment firm Greenlight Capital, Coya’s largest institutional shareholder, contributed $1.1 million.

The funding was raised through a definitive securities purchase agreement for the purchase and sale of more than 2.5 million shares of Coya's common stock in a private placement at $4.40 per share.

Coya reports that it plans to use the proceeds to scale up manufacturing of low-dose interleukin-2 (IL-2), which is a component of its COYA 302 and will support the commercial readiness of the drug. COYA 302 enhances anti-inflammatory T cell function and suppresses harmful immune activity for treatment of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s disease and Alzheimer’s disease.

The company received FDA acceptance for its investigational new drug application for COYA 302 for treating ALS and FTD this summer. Its ALSTARS Phase 2 clinical trial for ALS treatment launched this fall in the U.S. and Canada and has begun enrolling and dosing patients. Coya CEO Arun Swaminathan said in a letter to investors that the company also plans to advance its clinical programs for the drug for FTD therapy in 2026.

Coya was founded in 2021. The company merged with Nicoya Health Inc. in 2020 and raised $10 million in its series A the same year. It closed its IPO in January 2023 for more than $15 million. Its therapeutics uses innovative work from Houston Methodist's Dr. Stanley H. Appel.